```html

Zollinger‑Ellison Syndrome (Familial)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing neuroendocrine tumors (called gastrinomas) develop in the pancreas or duodenum. These tumors secrete large amounts of gastrin, a hormone that dramatically increases stomach acid production. The excess acid leads to severe peptic ulcers, diarrhea, and malabsorption.

The familial form of ZES occurs as part of an inherited disorder called multiple endocrine neoplasia type 1 (MEN 1). MEN 1 is caused by mutations in the MEN1 tumor‑suppressor gene and follows an autosomal‑dominant inheritance pattern, meaning a child has a 50 % chance of inheriting the mutation from an affected parent.

• Prevalence: Sporadic ZES occurs in ~1–3 per million people worldwide. Familial ZES (MEN 1‑associated) accounts for 20–30 % of all cases.<sup>1</sup>
• Age of onset: Median age at diagnosis is 30–40 years for familial cases, often a decade earlier than sporadic cases.
• Sex: Both men and women are equally affected.

Symptoms

Symptoms result from hyperacidic gastric secretions, tumor mass effect, and hormonal excess. Not every patient experiences every symptom.

Gastrointestinal

• Abdominal pain: Often epigastric, burning, and worsens with meals.
• Refractory peptic ulcers: Ulcers may be multiple, large, and located beyond the duodenum (e.g., jejunum).
• Diarrhea: Occurs in up to 70 % of patients; can be watery, fatty (steatorrhea), or both.
• Nausea & vomiting: Frequently present, especially after large meals.
• Gastric outlet obstruction: Rare, caused by ulcer scarring.

Systemic

• Weight loss: Due to malabsorption and chronic diarrhea.
• Fatigue & anemia: Chronic blood loss from ulcers or iron‑deficiency.
• Osteopenia/Osteoporosis: Persistent acid can impair calcium absorption.

MEN 1‑related manifestations (may coexist)

• Primary hyperparathyroidism (most common MEN 1 feature)
• Pituitary adenomas (prolactinoma, GH‑secreting tumors)
• Other pancreatic neuroendocrine tumors (e.g., insulinoma)

Causes and Risk Factors

Genetic Basis

The familial form is directly linked to germline mutations in the MEN1 gene on chromosome 11q13. The MEN1 protein (menin) regulates cell growth; loss of function enables unchecked proliferation of neuroendocrine cells, leading to gastrinomas.

Risk Factors

• Family history: A first‑degree relative with MEN 1 or ZES dramatically raises risk.
• Known MEN1 mutation: Carriers should undergo regular surveillance even if asymptomatic.
• Age: While any age is possible, most diagnoses occur between 20–45 years.
• Personal history of other MEN 1 tumors: Presence of hyperparathyroidism or pituitary adenoma suggests a higher likelihood of gastrinoma development.

Diagnosis

Because ZES can mimic common ulcer disease, a high index of suspicion is required, especially in patients with MEN 1.

Biochemical Tests

• Fasting serum gastrin: Levels > 1000 pg/mL (normally < 100 pg/mL) are highly suggestive. Levels between 100–1000 pg/mL require confirmatory testing.
• Secretin stimulation test: Intravenous secretin paradoxically raises gastrin > 120 pg/mL in ZES (sensitivity ≈ 95 %).
• pH monitoring: Gastric pH < 2 confirms hyperacidity.

Imaging Studies

• Endoscopic ultrasound (EUS): Highly sensitive for tumors ≤ 1 cm.
• Multiphasic contrast‑enhanced CT or MRI: Detects primary gastrinomas and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Gold standard for locating occult neuroendocrine tumors.

Genetic Testing

All patients with suspected familial ZES should undergo MEN1 gene sequencing. Positive results guide surveillance for other MEN 1 tumors and enable cascade testing of relatives.

Diagnostic Criteria (per NIH/WHO)

1. Elevated fasting gastrin ≥ 1000 pg/mL, or
2. Fasting gastrin 100–1000 pg/mL + positive secretin test, and
3. Imaging confirming gastrinoma (or MEN 1 mutation with compatible clinical picture).

Treatment Options

Management aims to (1) control acid hypersecretion, (2) eradicate or reduce tumor burden, and (3) monitor for MEN 1‑related neoplasms.

Acid‑Suppressive Medications

• High‑dose proton pump inhibitors (PPIs): Omeprazole 60 mg daily or equivalent; may be titrated to symptom control. PPIs normalize gastric pH, heal ulcers, and improve quality of life in > 90 % of patients.<sup>2</sup>
• Histamine‑2 receptor antagonists (H2RAs): Less effective alone but can be added for breakthrough symptoms.

Surgical Management

Indications include localized tumors, refractory disease despite maximal medical therapy, or presence of metastases amenable to resection.

• Enucleation: Preferred for small (< 2 cm), well‑circumscribed gastrinomas without lymph node involvement.
• Pancreaticoduodenectomy (Whipple) or distal pancreatectomy: Considered for larger or multiple tumors.
• Debulking surgery: May reduce hormone load in metastatic disease when complete resection is impossible.

Medical Oncology

• Somatostatin analogues (e.g., octreotide, lanreotide): Bind somatostatin receptors, suppress gastrin release, and can stabilize tumor growth.
• Targeted therapy (everolimus, sunitinib): Approved for advanced pancreatic neuroendocrine tumors; may be used when disease progresses despite somatostatin analogues.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor‑positive tumors; improves progression‑free survival in selected patients.

Liver‑Directed Therapies (for metastases)

• Radiofrequency ablation, trans‑arterial embolization, or selective internal radiation therapy (Y‑90).

Lifestyle & Supportive Measures

• Small, frequent meals; avoid foods that aggravate ulcer pain (spicy, acidic, caffeine).
• Stay hydrated; oral rehydration solutions for chronic diarrhea.
• Calcium and vitamin D supplementation to counteract malabsorption and prevent bone loss.

Living with Zollinger‑Ellison Syndrome (Familial)

Self‑Monitoring

• Track stool frequency, consistency, and any blood in stools.
• Maintain a symptom diary (pain, nausea, weight changes) to discuss with your gastroenterologist.
• Regularly check serum gastrin levels as directed (often every 6–12 months).

Surveillance for MEN 1

Because families with MEN 1 are at risk for multiple endocrine tumors, follow a structured screening schedule:

• Every 1–2 years: Serum calcium & PTH (hyperparathyroidism), fasting gastrin, prolactin, IGF‑1.
• Every 2–3 years: MRI of the pancreas, pituitary MRI, and parathyroid ultrasound.

Nutrition

• High‑protein, low‑fat diet to aid absorption.
• Consider pancreatic enzyme replacement if steatorrhea is severe.
• Limit alcohol and nicotine, both of which exacerbate ulcer disease.

Psychosocial Support

Living with a chronic rare disease can be stressful. Patient advocacy groups (e.g., MEN1.org) offer education, peer support, and resources for genetic counseling.

Prevention

Because the familial form is genetically predetermined, primary prevention is not possible. However, risk mitigation strategies include:

• Genetic counseling: Families with a known MEN1 mutation should receive counseling before conception to discuss reproductive options (e.g., pre‑implantation genetic diagnosis).
• Early detection: Routine screening of at‑risk relatives enables treatment before complications arise.
• Lifestyle measures: Avoiding NSAIDs, smoking, and excessive alcohol reduces ulcer risk, even in the presence of high gastrin.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory or perforated peptic ulcers – may cause intra‑abdominal bleeding or peritonitis.
• Severe malabsorption – chronic diarrhea and steatorrhea can cause nutritional deficiencies, anemia, and weight loss.
• Gastrointestinal bleeding – from ulcer erosion.
• Gastric outlet obstruction – due to scar tissue.
• Metastatic disease: Approximately 30–40 % of gastrinomas metastasize to the liver or lymph nodes, reducing long‑term survival.
• Bone disease: Chronic acid suppresses calcium absorption, leading to osteopenia/osteoporosis and increased fracture risk.
• MEN 1‑related cancers: Pituitary adenomas can cause visual field loss; hyperparathyroidism predisposes to kidney stones and renal impairment.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Cleveland Clinic,  J Clin Endocrinol Metab 2021;106(4):1234‑1245.

```